Letter to the Editor: Comments on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 vs insulin glargine in insulin naïve type 2 diabetes patients: cost effectiveness analysis in a UK setting

Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Current Medical Research and Opinion ◽

10.1185/030079906x00000 ◽

2006 ◽

Vol 22 (5) ◽

pp. 967-969 ◽

Cited By ~ 4

Author(s):

Craig J. Currie ◽

Phil McEwan ◽

Chris Poole ◽

William J. Valentine ◽

Andrew J. Palmer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

The Uk ◽

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Current Medical Research and Opinion ◽

10.1185/030079905x74989 ◽

2005 ◽

Vol 21 (12) ◽

pp. 2063-2071 ◽

Cited By ~ 24

Author(s):

William J. Valentine ◽

Andrew J. Palmer ◽

Morten Lammert ◽

Lars Nicklasson ◽

Volker Foos ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

The Uk ◽

PDB7 LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH, SWEDISH AND UK SETTINGS

Value in Health ◽

10.1016/s1098-3015(10)65950-5 ◽

2004 ◽

Vol 7 (6) ◽

pp. 736-737 ◽

Cited By ~ 1

Author(s):

M Lammert ◽

AJ Palmer ◽

S Roze ◽

ME Minshall ◽

WJ Valentine ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30

PDB24 COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING

Value in Health ◽

10.1016/s1098-3015(10)75002-6 ◽

2009 ◽

Vol 12 (7) ◽

pp. A405-A406

Author(s):

E Suchankova ◽

T Doležal ◽

Z Pisarikova ◽

K Rychna ◽

D Bartaskova

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Human Insulin ◽

Insulin Aspart ◽

Cost Effectiveness Analysis ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

Biphasic Insulin Aspart 30

An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes

Journal of Medical Economics ◽

10.3111/13696998.2014.991791 ◽

2015 ◽

Vol 18 (4) ◽

pp. 263-272 ◽

Cited By ~ 12

Author(s):

Vishal Gupta ◽

Ranya Baabbad ◽

Eva Hammerby ◽

Annie Nikolajsen ◽

Asrul Akmal Shafie

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Human Insulin ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Neutral Protamine Hagedorn ◽

The Cost

DB1 EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH OUTCOMES

Value in Health ◽

10.1016/s1098-3015(11)73078-9 ◽

2010 ◽

Vol 13 (7) ◽

pp. A507

Author(s):

J Chang ◽

F Sun ◽

H Li

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Health Outcomes ◽

Insulin Aspart ◽

Basal Insulin ◽

Biphasic Insulin ◽

The Cost

Short And Long-Term Cost-Effectiveness Of Switching Therapy From Biphasic Human Insulin 30 To Biphasic Insulin Aspart 30 In People With Type-2 Diabetes

Value in Health ◽

10.1016/j.jval.2013.03.819 ◽

2013 ◽

Vol 16 (3) ◽

pp. A164

Author(s):

P.D. Home ◽

P. Soewondo ◽

Z. Hussein ◽

A.A. Shafie ◽

K. AlRaddady ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Human Insulin ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Switching Therapy ◽

Short And Long Term

PDB51 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM HEALTH ECONOMIC ANALYSIS

Value in Health ◽

10.1016/s1098-3015(11)72109-x ◽

2010 ◽

Vol 13 (7) ◽

pp. A293 ◽

Cited By ~ 2

Author(s):

JL Palmer ◽

CG Pinto ◽

R Duarte ◽

L Miguel ◽

Z Gregor

Keyword(s):

Type 2 Diabetes ◽

Health Economic ◽

Cost Effectiveness ◽

Economic Analysis ◽

Insulin Glargine ◽

Insulin Aspart ◽

Health Economic Analysis ◽

Biphasic Insulin

PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES: LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN

Value in Health ◽

10.1016/s1098-3015(10)67639-5 ◽

2005 ◽

Vol 8 (6) ◽

pp. A160

Author(s):

AJ Palmer ◽

M Lammert ◽

WJ Valentine ◽

JA Ray ◽

AS Brandt ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Aspart ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

PDB11 CLINICAL AND COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 ONCE OR TWICE DAILY VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES MELLITUS: A MODELING ANALYSIS IN THE CHINESE SETTING

Value in Health ◽

10.1016/s1098-3015(11)73186-2 ◽

2010 ◽

Vol 13 (7) ◽

pp. A528

Author(s):

JL Palmer ◽

A Beaudet ◽

J White ◽

J Plun-Favreau ◽

J Smith-Palmer

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Modeling Analysis ◽

Biphasic Insulin Aspart 30